The positive association between GFPT1 and tumor progression, combined with its role in chemotherapy resistance, suggests that targeting GFPT1 could enhance the efficacy of current treatment strategies, particularly in patients with aggressive or advanced-stage disease. Here, GFPT1 is linked to neoplasm.